Dynamic Technology Lab Private Ltd Has $499,000 Stake in LifeMD, Inc. (NASDAQ:LFMD)

Dynamic Technology Lab Private Ltd raised its position in LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 134.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 100,836 shares of the company's stock after acquiring an additional 57,788 shares during the period. Dynamic Technology Lab Private Ltd owned approximately 0.23% of LifeMD worth $499,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. AXQ Capital LP acquired a new position in shares of LifeMD during the 4th quarter worth approximately $57,000. Quantbot Technologies LP purchased a new stake in LifeMD during the 4th quarter worth about $59,000. Prudential Financial Inc. lifted its holdings in LifeMD by 19.3% in the 4th quarter. Prudential Financial Inc. now owns 13,605 shares of the company's stock valued at $67,000 after purchasing an additional 2,200 shares in the last quarter. Magnus Financial Group LLC grew its holdings in shares of LifeMD by 31.1% during the fourth quarter. Magnus Financial Group LLC now owns 16,000 shares of the company's stock worth $79,000 after buying an additional 3,792 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of LifeMD by 44.7% during the fourth quarter. Wells Fargo & Company MN now owns 18,732 shares of the company's stock valued at $93,000 after buying an additional 5,791 shares during the period. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Stock Performance

Shares of LFMD stock traded up $0.16 during trading hours on Monday, reaching $5.19. The company had a trading volume of 62,886 shares, compared to its average volume of 814,391. The stock's fifty day simple moving average is $5.76 and its 200 day simple moving average is $5.43. The company has a market capitalization of $231.39 million, a P/E ratio of -8.11 and a beta of 2.22. LifeMD, Inc. has a twelve month low of $3.99 and a twelve month high of $12.88.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The firm had revenue of $64.26 million for the quarter, compared to analyst estimates of $57.43 million. As a group, equities analysts expect that LifeMD, Inc. will post -0.56 earnings per share for the current year.

Insider Transactions at LifeMD

In other news, CEO Justin Schreiber sold 50,000 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $7.55, for a total transaction of $377,500.00. Following the transaction, the chief executive officer now directly owns 2,653,715 shares in the company, valued at $20,035,548.25. The trade was a 1.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CMO Jessica Friedeman sold 30,000 shares of LifeMD stock in a transaction on Friday, March 14th. The shares were sold at an average price of $5.66, for a total value of $169,800.00. Following the sale, the chief marketing officer now directly owns 170,000 shares of the company's stock, valued at approximately $962,200. The trade was a 15.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 15.97% of the company's stock.

Wall Street Analyst Weigh In

LFMD has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and set a $15.00 price target on shares of LifeMD in a research note on Tuesday, March 11th. HC Wainwright raised their target price on shares of LifeMD from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Wednesday, March 12th. B. Riley upgraded shares of LifeMD to a "strong-buy" rating in a report on Tuesday, March 11th. Finally, KeyCorp cut their target price on LifeMD from $10.00 to $7.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, LifeMD currently has an average rating of "Buy" and an average price target of $11.43.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.